Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5-11 years of age in Brazil: A prospective test-negative design study.
Rodrigues CO, Spinardi J, Rosa RG, Falavigna M, de Souza EM, Manfio JL, de Souza AP, de Araujo CLP, Cohen M, Barbosa GRGDV, Silva FKR, Sganzerla D, da Silva MMD, Ferreira D, Kunkel NT, Camargo NI, Sarturi JC, Guilhem MC, de Oliveira JC, Lopes CC, Widmar F, Barufi LK, da Silva GN, Gradia DF, Brandalize APC, Royer CA, Luiz RM, Baura VA, Abreu H, Poitevin CG, Kucharski GA, Pedrotti F, Valluri SR, Srivastava A, Julião VW, Melone OC, Allen KE, Kyaw MH, Castillo GDCM, McLaughlin JM; Toledo BNT162b2 Study Group Investigators. Rodrigues CO, et al. Among authors: ferreira d. Immunol Lett. 2024 Oct;269:106903. doi: 10.1016/j.imlet.2024.106903. Epub 2024 Jul 26. Immunol Lett. 2024. PMID: 39069096
BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan.
Goulart Rosa R, Spinardi J, Allen KE, Manfio J, de Araujo CLP, Cohen M, Robinson CC, Sganzerla D, Ferreira D, de Souza EM, de Oliveira JC, Gradia DF, Brandalize APC, Kucharski GA, Pedrotti F, Rodrigues CO, Kyaw MH, Castillo GDCM, Srivastava A, McLaughlin JM, Falavigna M. Goulart Rosa R, et al. Among authors: ferreira d. PLoS One. 2022 Oct 20;17(10):e0276384. doi: 10.1371/journal.pone.0276384. eCollection 2022. PLoS One. 2022. PMID: 36264905 Free PMC article.
BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
Rosa RG, Falavigna M, Manfio JL, de Araujo CLP, Cohen M, do Valle Barbosa GRG, de Souza AP, Romeiro Silva FK, Sganzerla D, da Silva MMD, Ferreira D, de Oliveira Rodrigues C, de Souza EM, de Oliveira JC, Gradia DF, Brandalize APC, Royer CA, Luiz RM, Kucharski GA, Pedrotti F, Valluri SR, Srivastava A, Julião VW, Melone OC, Allen KE, Kyaw MH, Spinardi J, Del Carmen Morales Castillo G, McLaughlin JM; Toledo BNT16b2 Study Group Investigators. Rosa RG, et al. Among authors: ferreira d. Vaccine. 2023 Aug 23;41(37):5461-5468. doi: 10.1016/j.vaccine.2023.07.038. Epub 2023 Jul 26. Vaccine. 2023. PMID: 37507274 Free article.
A new N-acylhydrazone oxadiazole derivative with activity against mycobacteria.
Souza IV, Fróes da Motta Dacome ML, Frederico Rozada AM, Rosa JS, Sampiron EG, Ferreira DG, Gauze GF, Norman Negri MF, de Lima Scodro RB, Cardoso RF, Caleffi-Ferracioli KR. Souza IV, et al. Among authors: ferreira dg. Future Microbiol. 2024 Oct 23:1-12. doi: 10.1080/17460913.2024.2412439. Online ahead of print. Future Microbiol. 2024. PMID: 39440547
2,045 results